EFPIA Rejects EU Calls To Relax IP Protections
European Industry ‘Not Dependent On China & India’
State-imposed mechanisms such as compulsory licensing will discourage rather than encourage investment in R&D, says Europe’s research-based industry. It has also dismissed suggestions that Europe is too dependent on API supplies from third countries.
You may also be interested in...
Some way needs to be found to guarantee the supply of coronavirus products as more of them begin to become available, but the pharmaceutical industry says compulsory licensing is not the answer.
A resolution adopted by the EU’s legislative body includes ways of making Europe more resilient to future pandemics and supply chain risks, and ensuring equitable access to affordable vaccines and medicines. Proposals from the European Parliament to share IP and knowledge have been welcomed by medicines access campaigners.
A new EU-wide strategy on procuring potential COVID-19 vaccines through advance purchase agreements has been launched, replacing earlier fragmented efforts by some member states.